Shares of Aehr Test Systems surged 10.3% to $117.10 on August 11, extending a blistering run that has taken the stock from $79.98 on July 31 — a cumulative gain of roughly 46% in under two weeks. The catalyst: a follow-on production order for Aehr's automated wafer-testing system, purchased by a leading silicon photonics customer ramping capacity for optical connections used in AI data centers. With broader markets flat, this is a pure company-specific story — and it raises a pointed question about how much future growth is already priced in.

• A Record Backlog Underpins the Hype, but the Revenue Is Still Catching Up

Aehr's backlog ended its fiscal Q4 at a record $80.6 million, with effective backlog — including post-quarter orders — rising to roughly $100.6 million. Yet full fiscal-year 2026 revenue was just $50 million, a 15% decline from the prior year's $59 million. The new silicon photonics order adds to that backlog, but investors are essentially paying today for revenue that won't arrive until fiscal 2027 and beyond.

• The AI Pivot Is Real — and Management Is Betting the House on It

Aehr's business has been transitioning from an overwhelming focus on EV markets to one overwhelmingly focused on non-EV markets, including AI.

Record quarterly bookings and growing demand across AI processors, silicon photonics, and power semiconductors position the company for significant growth in 2027. The follow-on order validates that data-center customers are moving from trial purchases to production-scale commitments.

• Guidance Implies a Revenue Tripling — a High Bar to Clear

Management guided for fiscal 2027 revenue of $130 million to $150 million, far above fiscal 2026 sales of $50 million — implying roughly 160% to 200% year-over-year growth. Q4 adjusted gross margin soared 1,000 basis points to 45%, aided by AI-related demand , a sign that higher-value orders improve profitability. Still, moderate short interest and recent net insider selling highlight positioning risk.

• Valuation Has Run Far Ahead of Current Fundamentals

The stock has risen about 320% in 2026, with a market capitalization sitting at $2.7 billion as of mid-July — now likely north of $3.3 billion at today's price. Even against the high end of fiscal 2027 guidance, that's roughly 22 times forward sales. Analysts at Craig Hallum and Lake Street Capital have set price targets implying roughly 40% upside , but those targets were set before this latest leg higher. Execution on the enormous backlog — not new orders alone — will determine whether the stock's premium is justified.